M1 Kliniken AG

XTRA:M12 Stock Report

Market Cap: €276.5m

M1 Kliniken Future Growth

Future criteria checks 2/6

M1 Kliniken is forecast to grow earnings and revenue by 16% and 7.8% per annum respectively. EPS is expected to grow by 14.4% per annum. Return on equity is forecast to be 18.6% in 3 years.

Key information

16.0%

Earnings growth rate

14.4%

EPS growth rate

Healthcare earnings growth22.4%
Revenue growth rate7.8%
Future return on equity18.6%
Analyst coverage

Low

Last updated06 Jan 2025

Recent future growth updates

Recent updates

Does M1 Kliniken (ETR:M12) Have A Healthy Balance Sheet?

Oct 15
Does M1 Kliniken (ETR:M12) Have A Healthy Balance Sheet?

Earnings Not Telling The Story For M1 Kliniken AG (ETR:M12) After Shares Rise 27%

Sep 24
Earnings Not Telling The Story For M1 Kliniken AG (ETR:M12) After Shares Rise 27%

Why We're Not Concerned Yet About M1 Kliniken AG's (ETR:M12) 27% Share Price Plunge

Aug 03
Why We're Not Concerned Yet About M1 Kliniken AG's (ETR:M12) 27% Share Price Plunge

Additional Considerations Required While Assessing M1 Kliniken's (ETR:M12) Strong Earnings

Jun 06
Additional Considerations Required While Assessing M1 Kliniken's (ETR:M12) Strong Earnings

M1 Kliniken AG (ETR:M12) Looks Just Right With A 53% Price Jump

May 29
M1 Kliniken AG (ETR:M12) Looks Just Right With A 53% Price Jump

M1 Kliniken (ETR:M12) Might Be Having Difficulty Using Its Capital Effectively

May 03
M1 Kliniken (ETR:M12) Might Be Having Difficulty Using Its Capital Effectively

At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Mar 07
At €14.40, Is It Time To Put M1 Kliniken AG (ETR:M12) On Your Watch List?

Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Feb 18
Why Investors Shouldn't Be Surprised By M1 Kliniken AG's (ETR:M12) 25% Share Price Surge

Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?

Feb 17
Is M1 Kliniken AG (ETR:M12) Trading At A 46% Discount?

An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued

Sep 01
An Intrinsic Calculation For M1 Kliniken AG (ETR:M12) Suggests It's 27% Undervalued

Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?

Jun 01
Should You Think About Buying M1 Kliniken AG (ETR:M12) Now?

The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence

Mar 25
The Returns On Capital At M1 Kliniken (ETR:M12) Don't Inspire Confidence

Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital

Dec 17
Investors Could Be Concerned With M1 Kliniken's (ETR:M12) Returns On Capital

Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?

Nov 02
Is Now The Time To Look At Buying M1 Kliniken AG (ETR:M12)?

Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook

May 26
Time To Worry? Analysts Are Downgrading Their M1 Kliniken AG (ETR:M12) Outlook

Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results

May 25
Analysts Have Lowered Expectations For M1 Kliniken AG (ETR:M12) After Its Latest Results

Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital

Dec 06
Here's What's Concerning About M1 Kliniken's (ETR:M12) Returns On Capital

There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital

May 22
There Are Reasons To Feel Uneasy About M1 Kliniken's (ETR:M12) Returns On Capital

Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like

Mar 19
Here's What M1 Kliniken AG's (ETR:M12) Shareholder Ownership Structure Looks Like

We're Watching These Trends At M1 Kliniken (ETR:M12)

Feb 21
We're Watching These Trends At M1 Kliniken (ETR:M12)

M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment

Feb 03
M1 Kliniken (ETR:M12) Has Gifted Shareholders With A Fantastic 106% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?

Jan 16
Are Dividend Investors Getting More Than They Bargained For With M1 Kliniken AG's (ETR:M12) Dividend?

M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 29
M1 Kliniken AG's (ETR:M12) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 14
Here's Why We Don't Think M1 Kliniken's (ETR:M12) Statutory Earnings Reflect Its Underlying Earnings Potential

When Should You Buy M1 Kliniken AG (ETR:M12)?

Nov 28
When Should You Buy M1 Kliniken AG (ETR:M12)?

Earnings and Revenue Growth Forecasts

XTRA:M12 - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027441N/A31N/A2
12/31/20264052425292
12/31/20253721921242
12/31/20243461517222
6/30/2024333171920N/A
3/31/2024325141314N/A
12/31/20233161078N/A
9/30/20233078910N/A
6/30/202329761113N/A
3/31/202329151517N/A
12/31/202228541921N/A
9/30/202228762022N/A
6/30/202228872122N/A
3/31/202230281819N/A
12/31/202131591416N/A
9/30/20213049N/AN/AN/A
6/30/2021293101415N/A
3/31/202122681112N/A
12/31/20201607810N/A
9/30/20201187N/AN/AN/A
6/30/2020766-9-8N/A
3/31/2020778-8-7N/A
12/31/20197710-7-5N/A
9/30/2019738-4-2N/A
6/30/201969701N/A
3/31/201967702N/A
12/31/201865713N/A
9/30/2018606-11N/A
6/30/2018545-20N/A
3/31/2018516N/A1N/A
12/31/2017476N/A2N/A
9/30/2017436N/A5N/A
6/30/2017406N/A8N/A
3/31/2017385N/A8N/A
12/31/2016365N/A8N/A
9/30/2016407N/A7N/A
6/30/20164310N/A5N/A
3/31/2016398N/A3N/A
12/31/2015357N/A0N/A
12/31/2014235N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: M12's forecast earnings growth (16% per year) is above the savings rate (1%).

Earnings vs Market: M12's earnings (16% per year) are forecast to grow slower than the German market (19.3% per year).

High Growth Earnings: M12's earnings are forecast to grow, but not significantly.

Revenue vs Market: M12's revenue (7.8% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: M12's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: M12's Return on Equity is forecast to be low in 3 years time (18.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 20:21
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

M1 Kliniken AG is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlotte FriedrichsBerenberg
Stephan KleppCommerzbank AG
Edward AcklinFirst Berlin Equity Research GmbH